Amyotrophic Lateral Sclerosis as an Adverse Drug Reaction: A Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System-Reference-Cited by-同舟云学术

Amyotrophic Lateral Sclerosis as an Adverse Drug Reaction: A Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System

Published:2022-05-24 Issue:6 Volume:45 Page:663-673
ISSN:0114-5916
Container-title:Drug Safety
language:en
Short-container-title:Drug Saf

Author:

Gaimari Anna,Fusaroli Michele,Raschi Emanuel,Baldin Elisa,Vignatelli Luca,Nonino Francesco,De Ponti Fabrizio,Mandrioli Jessica^ORCID,Poluzzi Elisabetta

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Toxicology

Link

https://link.springer.com/content/pdf/10.1007/s40264-022-01184-1.pdf

Reference52 articles.

1. Oskarsson B, Gendron TF, Staff NP. Amyotrophic lateral sclerosis: an update for 2018. Mayo Clin Proc. 2018;93:1617–28. https://doi.org/10.1016/j.mayocp.2018.04.007.

2. Schultz J. Disease-modifying treatment of amyotrophic lateral sclerosis. Am J Manag Care. 2018;24:S327–35.

3. Jaiswal MK. Calcium, mitochondria and the pathogenesis of ALS: the good, the bad and the ugly. Front Cell Neurosci. 2013;7:199. https://doi.org/10.3389/fncel.2013.00199.

4. Mariosa D, Kamel F, Bellocco R, Ronnevi LO, Almqvist C, Larsson H, et al. Antidiabetics, statins and the risk of amyotrophic lateral sclerosis. Eur J Neurol. 2020;27:1010–6. https://doi.org/10.1111/ene.14190.

5. Cetin H, Sun J, Almqvist C, Reichardt B, Tomschik M, Zimprich F, et al. No association between proton pump inhibitor use and ALS risk: a nationwide nested case–control study. Sci Rep. 2020;10:13371. https://doi.org/10.1038/s41598-020-70373-8.

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of statins in amyotrophic lateral sclerosis: protective or not?;Frontiers in Neuroscience;2024-06-05

2. Development and validation of a stability-indicating analytical method for simultaneous determination of sodium phenylbutyrate and taurursodiol in bulk and formulation using reverse phase ultra-performance liquid chromatography;Egyptian Pharmaceutical Journal;2024-02-27

3. Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems;Frontiers in Drug Safety and Regulation;2024-01-26

4. Comment on: Exploring the association between weight loss-inducing medications and multiple sclerosis: insights from the FDA adverse event reporting system database;Therapeutic Advances in Neurological Disorders;2024-01

5. Micheliolide prevents estrogen deficiency-induced bone loss via inhibiting osteoclast bone resorption;Aging;2023-10-11